SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-012729
Filing Date
2023-08-01
Accepted
2023-08-01 16:15:29
Documents
72
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q knsa-20230630x10q.htm   iXBRL 10-Q 2305120
2 EX-10.1 knsa-20230630xex10d1.htm EX-10.1 51908
3 EX-31.1 knsa-20230630xex31d1.htm EX-31.1 11329
4 EX-31.2 knsa-20230630xex31d2.htm EX-31.2 10485
5 EX-32.1 knsa-20230630xex32d1.htm EX-32.1 6291
6 EX-32.2 knsa-20230630xex32d2.htm EX-32.2 6265
  Complete submission text file 0001558370-23-012729.txt   8515061

Data Files

Seq Description Document Type Size
7 EX-101.SCH knsa-20230630.xsd EX-101.SCH 53376
8 EX-101.CAL knsa-20230630_cal.xml EX-101.CAL 58072
9 EX-101.DEF knsa-20230630_def.xml EX-101.DEF 256793
10 EX-101.LAB knsa-20230630_lab.xml EX-101.LAB 468044
11 EX-101.PRE knsa-20230630_pre.xml EX-101.PRE 372917
66 EXTRACTED XBRL INSTANCE DOCUMENT knsa-20230630x10q_htm.xml XML 1440793
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11 7814399100
Kiniksa Pharmaceuticals, Ltd. (Filer) CIK: 0001730430 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38492 | Film No.: 231131896
SIC: 2834 Pharmaceutical Preparations